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ABSTRAK
Latar belakang: seorang pasien dengan riwayat tuberkulosis (TBC) memiliki risiko hingga 27% untuk 
mengalami kekambuhan dalam 2 tahun setelah disembuhkan. Indonesia sendiri memiliki lebih dari 7.500 kasus 
berulang setiap tahun, terlepas dari reinfeksi atau kambuh. Ini adalah masalah penting, karena TB berulang 
dikaitkan dengan tingkat kesembuhan yang lebih rendah dengan terapi anti-TB dan risiko pengembangan 
resistansi obat yang lebih tinggi. Beberapa faktor risiko kekambuhan ini adalah merokok, kepatuhan pengobatan 
yang buruk, status ekonomi rendah, dan status kekebalan tubuh lemah. Laporan ini bertujuan mengidentifikasi 
apakah pasien dengan obat anti tuberkulosis (OAT) kombinasi dosis tetap (KDT) dalam pengobatan TBC lebih 
berisiko untuk kambuh dibandingkan pasien dengan pengobatan OAT dosis terpisah. Metode: pencarian literatur 
dilakukan di MEDLINE, ProQuest, EBSCO, ScienceDirect, dan Cochrane berdasarkan pertanyaan klinis dan 
pemilihan artikel sesuai kriteria inklusi dan eksklusi. Artikel yang terpilih dilakukan telaah kritis untuk menilai 
validitas, kepentingan, dan penerapannya. Hasil: hasil pencarian literatur didapatkan 5 studi kohort dengan 
validitas yang sama. Hanya satu studi yang memiliki nilai RR akurat sebesar 3,97 (1,14 – 13,80) dan NNH 18. 
Empat studi dapat diterapkan pada pasien kami. Kesimpulan: penggunaan OAT KDT dalam pengobatan TB 
meningkatkan risiko kekambuhan dibandingkan OAT dosis terpisah.
Kata kunci: kombinasi dosis tetap, tuberkulosis, kambuh.
ABSTRACT
Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 
2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection 
or relapse. This is an important problem, as recurrent TB is associated with lower cure rates with the anti-TB 
therapy and higher risk of developing drug resistance. Some risk factors for this recurrence are smoking, poor 
treatment adherence, low economic status, and weak immune status. This study is aimed to identify whether the 
use of fixed-dose combination (FDC) anti-tuberculosis therapy increases the risk for tuberculosis recurrence 
compared with using separate drug formulation. Methods: the search was conducted on MEDLINE, ProQuest, 
EBSCO, ScienceDirect, and Cochrane according to clinical question. The studies were selected based on inclusion 
and exclusion criteria and led to five useful articles. The selected studies were critically appraised for their 
validity, importance, and applicability. Results: five cohort studies were found with comparable validity. Only 
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1 study has accurate relative risk (RR) with 3.97 (1.14 – 13.80) and number needed to harm of 18. Other four 
studies fulfilled the applicability criteria for our case. Conclusion: the use of FDC anti-tuberculosis therapy 
increases the risk for tuberculosis recurrence compared with using separate drug formulation.
Keywords: fixed-dose combination, tuberculosis, recurrent.
INTRODUCTION
Tuberculosis (TB) remains a major global 
health problem, with an estimated 10.4 million 
incident cases and 1.4 million deaths in 2015 
according to the World Health Organization 
(WHO).1 In Indonesia, there were an estimated 
441,940 new active TB cases in 2011 with total 
economic burden roughly US$ 2.1 billion.2 
Moreover, strains of Mycobacterium tuberculosis 
that are resistant to standard anti-TB therapy 
are emerging in 155 countries, accounting for 
more than 95% of the world’s population.1 
Low compliance to treatment regimen and 
inappropriate prescription of TB therapy are 
believed to be major contributing factors to thus 
public health problems.3,4
Since 1994, WHO and the International 
Union against Tuberculosis and Lung Disease 
(IUATLD) have recommended the use of fixed-
dose combination (FDC) anti-TB therapy.5 This is 
to simplify the therapy, increase the compliance, 
and prevent the inadvertent medication errors.3,6,7 
However, concerns were raised about the 
possibility of poor rifampicin bioavailability, 
unstable blister-package of FDCs, and weak 
absorption rate.6,8 Many observational studies 
and clinical trials have been conducted to assess 
the effectiveness of FDCs with conflicting 
results.3 Currently, the main drugs for standard 
TB therapy are rifampicin (R), isoniazid (H), 
pyrazinamide (Z), and ethambutol (E). The FDCs 
include two-drug formulations (R+H and H+E), 
three-drug formulations (R+H+E and R+H+Z), 
and a four-drug formulation (R+H+Z+E).
Despite all of that, recurrence of TB is quite 
high. A patient with a history of TB has a risk 
up to 27% to develop recurrence within 2 years 
after being cured.9 Indonesia itself has more 
than 7,500 recurrent cases annually, regardless 
of reinfection or relapse.10 This is an important 
problem, as recurrent TB is associated with lower 
cure rates with the anti-TB therapy and higher 
risk of developing drug resistance. Some risk 
factors for this recurrence are smoking, poor 
treatment adherence, low economic status, and 
weak immune status.11 The aim of this evidence-
based case report (EBCR) is to critically analyzed 
whether the use of FDC anti-TB therapy 
increases the risk for TB recurrence compared 
with using separate drug formulation.
CLINICAL QUESTION
A 56-year old woman came to the clinic 
with chronic cough for three months prior to 
admission. She was a merchant with a history 
of TB six years ago. She had had FDC anti-TB 
therapy for 6 months and had been declared 
cured by her attending physician at that time. 
In her family, his son had TB two years ago and 
has been cured, while her step father is being 
treated for TB right now. Her sputum smear 
was positive. The patient was diagnosed with 
recurrent TB and had a category II anti-TB 
therapy according to the Indonesian guideline. 
She lived in a small tenement with her two sons 
in a very dense district.
The patient’s step father is being treated with 
separate drug regimen in a different clinic. She 
became curious of the difference between FDC 
and separate drug regimen. She was wondering 
whether there was a difference in terms of drug 
quality between those two and that was the cause 
of her recurrent TB.
In a woman with a newly diagnosed TB, does 
the use of FDC anti-TB therapy have a higher risk 
of TB recurrence compared with using separate 
drug formulation?
METHODS
A search of literatures was performed 
on June 23th to 25th, 2016 in six databases, 
including MEDLINE®, ProQuest®, EBSCO®, 
ScienceDirect®, and Cochrane®. The keywords 
were “tuberculosis”, “fixed-dose”, and “recurrent” 
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Figure 1. Flowchart of search strategy
Table 1. Terminology used in six databases
Database Terminology Hits
MEDLINE®
((“Tuberculosis”[Mesh]) AND ((((fixed-dose[Title/Abstract]) OR fixed dose[Title/
Abstract]) OR fixed-drug[Title/Abstract]) OR fixed drug[Title/Abstract])) AND 
((((recurrence[Title/Abstract]) OR recurrent[Title/Abstract]) OR relapse[Title/
Abstract]) OR reinfection[Title/Abstract])
13
ProQuest® ab(tuberculosis) AND ab((recurrent OR relapse OR reinfection)) AND 
ab((fixed-dose OR fixed dose OR fixed-drug OR fixed drug))
1
EBSCO®
AB tuberculosis AND AB (recurrent OR relapse OR reinfection) AND AB (fixed-
drug OR fixed drug OR fixed-dose OR fixed dose) 14
Science Direct®
TITLE-ABSTR-KEY(tuberculosis) AND TITLE-ABSTR-KEY(“recurrent” OR 
“relapse” OR “reinfection”) AND TITLE-ABSTR-KEY(“fixed-dose” OR “fixed 
dose” OR “fixed-drug” OR “fixed drug”)
1
Cochrane®
“tuberculosis” in Title, Abstract, Keywords AND “fixed-drug” OR “fixed drug” 
OR “fixed-dose” OR “fixed dose” in Title, Abstract, Keywords AND “recurrent” 
OR “reinfection” OR “relapse” in Title, Abstract, Keyword
1
with their synonyms and related terms. Eligible 
articles were clinical trials, systematic reviews, 
or meta-analyses that point TB recurrence as the 
outcome. Guidelines and review articles were 
excluded. The search strategy, results, and the 
inclusion-exclusion criteria are shown in Figure 
1. After literature selection, critical appraisal was 
done by consensus of all authors using several 
aspects based on Center of Evidence-Based 
Medicine, University of Oxford for harm or 
etiology study.
RESULTS
Following the search strategy, five original 
articles were eligible for this evidence-based 
case report.8,12-15 The design and summary 
of result is available on Table 2. The critical 
appraisal is shown on Table 3. All articles were 
cohort studies with level of evidence 2b. Study 
from Nunn et al.15 had the largest sample size 
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Table 2. Design and result of the selected articles
Article Year Design Drug regimen
Result
(adjusted with  
per-protocol analysis)
Zhang et al.12 1996 RCT 2RHZ/4RH
The FDCs were Rifater® for the first 2 months and 
Rifinah® for the next 4 months. No information regarding 
the manufacturer of the separate drugs.
Fixed-dose combination group:
 - Rifater® consists of R 120 mg + H 80 mg + Z 250 mg, 3 
tablets for body weight 30-39 kg, 4 tablets for 40-49 kg, 
and 5 tablets for ≥50 kg.
 - Rifinah®-150 consists of R 150 mg + H 100 mg, 3 
tablets for body weight <50 kg; or Rifinah®-300 consists 
of R 300 mg + H 150 mg, 2 tablets for ≥50 kg.
Separate-drug group:
 - For the first 2 months;
R 450 mg + H 300 mg + Z 1500 mg for body weight 
<50 kg,
R 600 mg + H 300 mg + Z 1500 mg for body weight 
≥50 kg.
 - For the next 4 months;
R 450 mg + H 300 mg for body weight <50 kg,
R 600 mg + H 300 mg for body weight ≥50 kg.
Relapse after 2 years
 - FDC group: 2 of 
102 patients
 - Separate-drug 
group: 2 of 103 
patients
Suryanto et al.8 2008 RCT 2RHZE/3R3H3 using WHO recommended formulation.
The FDCs were produced by Svizera Netherlands. No 
information regarding the manufacturer of the separate 
drugs.
Fixed-dose combination group:
 - Average 4FDC adult dose contains R 450 mg + H 225 
mg + Z 1200 mg + E 825 mg.
 - Average 2FDC adult dose contains R 450 mg + H 450 
mg.
Separate-drug group:
 - Average adult dose for the first 2 months contains R 
450 mg + H 300 mg + Z 1500 mg + E 750 mg.
 - Average adult dose for the next 3 months contains R 
450 mg + H 600 mg.
Relapse after 3-6 years
 - FDC group: 10 of 
236 patients
 - Separate-drug 
group: 2 of 198 
patients
Nunn et al.15 2014 RCT 2RHZE/4R3H3 using WHO recommended formulation.
The FDCs were produced by Svizera India. No information 
regarding the manufacturer of the separate drugs.
Fixed-dose combination group:
 - 4FDC consists of R 150 mg + H 75 mg + Z 400 mg + E 
275 mg, 2 tablets for body weight 30-37 kg, 3 tablets for 
38-54 kg, 4 tablets for 55-70 kg, and 5 tablets > 70 kg.
 - 2FDC consists of R 150 mg + H 150 mg, 2-5 tablets 
respectively based on the body weight.
Separate-drug group:
 - For the first 2 months;
R 300 mg + H 150 mg + Z 800 mg + E 600 mg for body 
weight 30-37 kg,
R 450 mg + H 250 mg + Z 1200 mg + E 800 mg for 
body weight 38-54 kg,
R 600 mg + H 300 mg + Z 1600 mg + E 1200 mg for 
body weight 55-70 kg,
or R 750 mg + H 350 mg + Z 2000 mg + E 1400 mg for 
body weight > 70 kg,
 - For the next 4 months;
2FDC consists of R 150 mg + H 150 mg, 2-5 tablets 
respectively based on the body weight.
Relapse after 30 
months
 - FDC group: 5 of 
683 patients
 - Separate-drug 
group: 0 of 671 
patients
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Table 2. Design and result of the selected articles
Article Year Design Drug regimen
Result
(adjusted with  
per-protocol analysis)
Su et al.14 2002 RCT 2RHZE/4RHE
No information regarding the manufacturer of the separate 
drugs.
Fixed-dose combination group:
 - Rifater® + E for the first 2 months, followed by Rifinah® 
+ E for 4 months.
 - Rifater® consists of R 120 mg + H 50 mg + Z 250 mg, 3 
tablets for body weight 30-39 kg, 4 tablets for 40-49 kg, 
and 5 tablets for ≥ 50 kg.
 - Rifinah®-150 consists of R 150 mg + H 100 mg, 
3 tablets for body weight < 50 kg; or Rifinah®-300 
consists of R 300 mg + H 150 mg, 2 tablets for body 
weight ≥ 50 kg
Separate-drug group:
 - For the first 2 months;
R 450 mg + H 300 mg + Z 1500 mg + E 1200 mg for 
body weight < 50 kg,
R 600 mg + H 300 mg + Z 1500 + E 1200 mg mg for 
body weight ≥ 50 kg.
 - For the next 4 months;
R 450 mg + H 300 mg + E 800 mg for body weight < 
50 kg,
R 600 mg + H 300 mg + E 800 mg for body weight ≥ 
50 kg.
Relapse after 2 years
 - FDC group: 1 of 57 
patients
 - Separate-drug 
group: 0 of 48 
patients
Teo et al.13 1999 RCT There were 3 variations of the regimen: 2SHRZ/4H3R3, 
1SHRZ/5H3R3, or 2HRZ/4H3R3. No further explanation 
regardless the selection criteria.
Fixed-dose combination group:
 - For the initial daily phase, RHZ was given as Rifater® 
(R 120 mg + H 50 mg + Z 300 mg). The daily dosage 
was 4 tablets for patients weighing ≤ 42 kg, 5 tablets for 
43-57 kg, or 6 tablets for ≥ 58 kg.
 - Streptomycin was given in a fixed-dose injection of 750 
mg, regardless of body weight.
 - For the continuation phase, H 600 mg for patients 
weighing ≤ 42 kg, 800 mg for 43-57 kg, or 1000 mg 
for ≥ 58 kg. Additional R 1200 mg were also given, 
regardless of body weight.
Separate-drug group:
 - For the initial daily phase, R 450 mg + H 300 mg + Z 
1500 mg for patients weighing ≤ 42 kg, R 600 mg + H 
300 mg + Z 1500 mg for 43-57 kg, or R 600 mg + H 300 
mg + Z 2000 mg for ≥ 58 kg.
 - Streptomycin was given in a fixed-dose injection of 750 
mg, regardless of body weight.
 - For the continuation phase, H 600 mg for patients 
weighing ≤ 42 kg, 800 mg for 43-57 kg, or 1000 mg 
for ≥ 58 kg. Additional R 1200 mg were also given, 
regardless of body weight.
Relapse after 5 years
 - FDC group: 12 of 
154 patients.
 - Separate-drug 
group: 3 of 153 
patients.
R: rifampicin; H: isoniazid; Z: pyrazinamide; E: ethambutol; S: streptomycin
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compared to the others, yet its loss to follow-up 
was unknown.Only one study from Su et al. had 
more than 20% loss to follow-up.14
All studies were considered to have good 
validity, although there were some unfulfilled 
components. The groups were similar, clearly 
defined, and had complete and adequate follow-
up. In terms of Hill’s criteria for causation, all 
studies met the criteria of temporality, consistency, 
and plausibility.16 Biological gradient could not 
be assessed because dose-response gradient and 
dechallenge-rechallenge could not be done in 
this type of study. The patients were not blinded 
as FDC had distinct appearance compared to 
separate drug formulation. No studies used 
additional method to make both regimens look 
alike. The studies also did not state whether they 
were all blinded or not for the assessment of the 
outcomes.
From the aspect of importance and 
applicability, all studies had a relative risk (RR) 
above 1. The RRs were adjusted to per-protocol 
analysis for the critical appraisal. Only one of 
which had a 95% confidence interval (CI) did 
not pass below the value of 1.13 All studies 
were relevant to our case with similar sample’s 
characteristics.
Table 3. Critical appraisal of the five studies based on criteria by Center of Evidence-Based Medicine, University of Oxford








































































Zhang et al.12, 
1996 2b 205 1,9 + ? + + RR 1.01 (0.14 – 7.00) 5.253 +
Suryanto et al.8, 
2008
2b 434 19,3 + ? + + RR 1.16 (0.58 – 2.31) 95 +
Nunn et al.15, 
2014
2b 1.354 n/a + - + + RR 10.81 (0.60 – 195.07) 137 +
Su et al.14, 2002 2b 105 51,4 + ? - + RR 2.53 (0.11 – 60.82) 64 +
Teo et al.13, 1999 2b 307 18 + ? + + RR 3.97 (1.14 – 13.80) 18 +
+ stated clearly in the article; - not being done; ? not stated clearly; levels of evidence based on Oxford Centre for 
Evidence-based Medicine; RR: relative risk; OR: odds ratio; CI: confidence interval; NNH: number needed to harm.
DISCUSSION
All studies reported a tendency of increased 
risk of TB recurrence with the use of FDC 
regimen.8,13-15 However, four studies had 
inaccurate 95% CI, probably due to the large 
number of loss to follow-up.
Based on the validity components, all five 
studies were adequately valid. These five studies 
were cohort with long exposure (six months) and 
a follow-up period of over a year, thus increasing 
the risk of loss to follow-up. Su et al. study 
had notably a 51.4% loss to follow-up that we 
fear will affect the validity of the study itself.14 
This was mainly caused by adverse effects and 
treatment defaults that were equal in both FDC 
and separate formulation groups. There was also 
a risk of unequal measurement in both FDC and 
separate formulation groups during the follow-
up of these studies, as the patients were aware of 
their regimen and the investigators could realize 
it. From the importance aspect, only Teo et al.13 
study that can be said to be accurate with RR 
3.97 (1.14–13.80). Therefore, his study is the 
best evidence we have at this time.
Another limitation of this report is the 
heterogenicity of intervention models. The drug’s 
dose and treatment regimens were different 
between articles. The FDCs among the articles 
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were produced from different manufacturers, as 
three articles used RIfater® and Rifinah® while 
the rest used another FDC by Svizera. There 
was also no information about the manufacturer 
of the separate drugs. Hence, this could be a 
potential bias for comparing the efficacy of the 
tuberculosis treatments.
Fixed-dose combination has been the main 
preference of anti-TB therapeutic regimen 
since about 20 years ago, especially due to 
its simplicity.5 However, recent meta-analysis 
concludes that there is no evidence of improved 
compliance and treatment satisfaction with the 
use of FDC.3 Recent findings from Indonesia also 
show that patient’s adherence is multifactorial, 
not only affected by the treatment regimen but 
also healthcare accessibility, knowledge, and 
especially perception of TB therapy.17,18
The exact cause of how FDCs affect TB 
recurrence is still not clearly known. It was 
reported that the bioavailability of rifampicin 
was reduced in FDCs, due to its enhanced 
decomposition in the presence of isoniazid.3,8 
The blister-packed FDCs have also been 
shown to be unstable, and their absorption was 
insufficient in immunocompromised patients.8 
The fixed-dose model may also impede further 
dose adjustments.6
For the application in our case, we should 
explain to our patient that the evidence is still 
limited, yet there is a tendency that the FDC 
formulations are inferior compared to separate 
drug regimen. However, the patient should be 
educated that recurrence is also multifactorial, 
as her family history and environmental factors 
also play important roles.19
CONCLUSION
In conclusion, FDC therapy is associated 
with a trend toward increased risk of TB 
recurrence. Even though FDC is easier and 
simpler for both the patient and the physician, 
this report does not support the use of FDC for 
treating newly diagnosed TB patients. Further 
research with better trial designs are needed 
to simulate real-world clinical practice while 
minimizing confounding, thus providing high-
quality evidence for health care policies and 
clinical decisions.
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